C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis
Stroke · 2023-05 · 54 (5) · 1289-1299
DOI: 10.1161/strokeaha.122.040529 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Stroke, 2023-05. Verfasst von John J McCabe und 18 weiteren Autor:innen. Beteiligte Einrichtung: Health Research Board (HRB) Stroke Clinical Trials Network Ireland (SCTNI), Dublin, Ireland (J.J.M., C.W., S.G., P.J.K.). Hauptthemen laut MEDLINE: Ischemic Attack, Transient, Stroke, Ischemic Stroke. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Anti-inflammatory therapies reduce recurrent vascular events in coronary disease. Existing studies have reported highly conflicting findings for the association of blood inflammatory markers with vascular recurrence after stroke leading to uncertainty about the potential of anti-inflammatory therapies after stroke and no consensus about the utility of measurement of inflammatory markers in current guidelines.
Methods
We investigated the association between hsCRP (high-sensitivity C-reactive protein), IL-6 (interluekin-6), and recurrent major adverse cardiovascular events (MACE), and stroke from individual participant data from 8420 patients with ischemic stroke/transient ischemic attack from 10 prospective studies. We did within-study multivariable regression analyses and then combined adjusted risk ratio (RR) by random-effects meta-analysis.
Results
During 18 920 person-years of follow-up, 1407 (16.7% [95% CI, 15.9–17.5]) patients had MACE and 1191 (14.1% [95% CI, 13.4–14.9]) patients had recurrent stroke. On bivariate analysis, baseline IL-6 was associated with MACE (RR, 1.26 [95% CI, 1.10–1.43]) and recurrent stroke (RR, 1.18 [95% CI, 1.05–1.32]), per unit increase log e IL-6. Similar associations were observed for hsCRP (MACE RR, 1.19 [95% CI, 1.09–1.29]; recurrent stroke RR, 1.12 [95% CI, 1.04–1.21], per unit increase log e hsCRP). After adjustment for vascular risk factors and treatment, independent associations remained with MACE (IL-6, RR, 1.12 [95% CI, 1.04–1.21]; hsCRP, RR, 1.09 [95% CI, 1.04–1.15]) and recurrent stroke (IL-6, RR, 1.09 [95% CI, 1.00–1.19]; hsCRP, RR, 1.05 [95% CI, 1.00–1.11]). Comparing the top with the bottom quarters (Q4 versus Q1), IL-6 (RR, 1.35 [95% CI, 1.09–1.67]) and hsCRP (RR, 1.31 [95% CI, 1.07–1.61]) were associated with MACE after adjustment. Similar results were observed for recurrent stroke for IL-6 (RR, 1.33 [95% CI, 1.08–1.65]) but not hsCRP (RR, 1.16 [95% CI, 0.93–1.43]).
Conclusions
Blood markers of inflammation were independently associated with vascular recurrence after stroke, strengthening the rationale for randomized trials of anti-inflammatory therapies for secondary prevention after ischemic stroke/TIA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Research Board (HRB) Stroke Clinical Trials Network Ireland (SCTNI), Dublin, Ireland (J.J.M., C.W., S.G., P.J.K.).
- School of Medicine, University College Dublin (UCD), Ireland (J.J.M., S.G., P.J.K.).
- Department of Geriatric Medicine (J.J.M., S.G.), Mater Misericordiae University Hospital, Dublin, Ireland.
- Health Research Institute and Mathematics Applications Consortium for Science and Industry (MACSI), Department of Mathematics and Statistics, University of Limerick, Ireland (C.W.).
- George Institute for Global Health, University of New South Wales, Sydney, Australia (K.H., M.W.).
- Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neuroscience Research Laboratory, Health Research Institute of Santiago de Compostela, Spain (P.H., R.I.-R.).
ORCID-Profile: John J McCabe, Cathal Walsh, Sarah Gorey, Katie Harris, Christina Jern, Linxin Li, Joan Montaner, Francisco Purroy, Peter M Rothwell, Catherine Sudlow, Yuji Ueno, Mikel Vicente-Pascual, William Whiteley, Mark Woodward, Peter J Kelly
Zitieren
APA
McCabe, J. J., Walsh, C., Gorey, S., Harris, K., Hervella, P., Iglesias-Rey, R., Jern, C., Li, L., Miyamoto, N., Montaner, J., Pedersen, A., Purroy, F., Rothwell, P. M., Sudlow, C., Ueno, Y., Vicente-Pascual, M., Whiteley, W., Woodward, M., & Kelly, P. J. (2023). C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis. Stroke, 54(5), 1289-1299. https://doi.org/10.1161/strokeaha.122.040529
Vancouver
McCabe JJ, Walsh C, Gorey S, Harris K, Hervella P, Iglesias-Rey R, et al. C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis. Stroke. 2023;54(5):1289-1299. doi:10.1161/strokeaha.122.040529
BibTeX
@article{McCabe2023,
author = {McCabe, John J and Walsh, Cathal and Gorey, Sarah and Harris, Katie and Hervella, Pablo and Iglesias-Rey, Ramon and Jern, Christina and Li, Linxin and Miyamoto, Nobukazu and Montaner, Joan and Pedersen, Annie and Purroy, Francisco and Rothwell, Peter M and Sudlow, Catherine and Ueno, Yuji and Vicente-Pascual, Mikel and Whiteley, William and Woodward, Mark and Kelly, Peter J},
title = {C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis},
journal = {Stroke},
year = {2023},
volume = {54},
number = {5},
pages = {1289--1299},
doi = {10.1161/strokeaha.122.040529}
}
EUVIMED